News
GHRS
23.84
-2.49%
-0.61
Weekly Report: what happened at GHRS last week (0914-0918)?
Weekly Report · 5d ago
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
Seeking Alpha · 6d ago
Weekly Report: what happened at GHRS last week (0907-0911)?
Weekly Report · 09/14 09:21
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference
TipRanks · 09/11 11:28
FDA names acting heads of drug and vaccine units to permanent roles
Seeking Alpha · 09/09 00:25
Weekly Report: what happened at GHRS last week (0831-0904)?
Weekly Report · 09/07 09:19
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS), Evaxion Biotech (EVAX) and Ibio (IBIO)
TipRanks · 08/31 14:00
Weekly Report: what happened at GHRS last week (0824-0828)?
Weekly Report · 08/31 09:21
Weekly Report: what happened at GHRS last week (0817-0821)?
Weekly Report · 08/24 09:21
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Seeking Alpha · 08/21 20:10
Weekly Report: what happened at GHRS last week (0810-0814)?
Weekly Report · 08/17 09:22
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)
TipRanks · 08/11 02:20
Weekly Report: what happened at GHRS last week (0803-0807)?
Weekly Report · 08/10 09:20
RBC Capital Remains a Buy on GH Research (GHRS)
TipRanks · 08/08 01:45
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)
TipRanks · 08/07 20:30
GH Research Is Maintained at Buy by Guggenheim
Dow Jones · 08/07 17:17
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Benzinga · 08/07 17:07
GH Research Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 08/07 12:35
GH Research Price Target Raised to $40.00/Share From $35.00 by Cantor Fitzgerald
Dow Jones · 08/07 12:35
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Benzinga · 08/07 12:25
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.